Rob Roscow: Psilocybin Through A Biopharmaceutical Lens

<p>In this episode we welcome Rob Roscow, Co-Founder &amp; Chief Scientific Officer at Mydecine Innovations Group.</p><br><p>Mydecine has government, military, and academic research contracts across numerous countries and is heavily invested in development of a novel molecule pipeline that includes treatments intended for smoking cessation and treatment of PTSD.</p><br><p>I had a chance to meet Ron and the Mydecine team in-person at the 2021 Telluride Mushroom Festival, which was sponsored by Mydecine.</p><br><p>This episode dives into the drug development pipeline and the challenges and opportunities of examine psilocybin and the entourage effect of mushrooms through a biopharmaceutical lens.</p><br><p>It's an arena of study which I am largely unfamiliar with, but which is becoming increasingly important in lobbying for the mainstream acceptance and regulatory scrutiny of psychedelic medicines as legitimate and effective therapeutic tools. </p><br /><hr><p style='color:grey; font-size:0.75em;'> See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for privacy and opt-out information.</p>